## Page 1

Hindawi Publishing Corporation
Evidence-Based Complementary and Alternative Medicine
Volume 2014, Article ID 682014, 9 pages
http://dx.doi.org/10.1155/2014/682014
Research Article
Proof-of-Concept Randomized Controlled Study of
Sceletium
Cognition Effects of the Proprietary Extract
tortuosum
(Zembrin) Targeting Phosphodiesterase-4 in
Cognitively Healthy Subjects: Implications for
Alzheimer‚Äôs Dementia
SimonChiu,1,2NigelGericke,3MichelFarina-Woodbury,4VladimirBadmaev,5
HanaRaheb,1KristenTerpstra,1JoalexAntongiorgi,4YvesBureau,1
ZackCernovsky,1,2JiruiHou,1VeronicaSanchez,1MarissaWilliams,1
JohnCopen,6MariwanHusni,7andLizGoble1
1LawsonHealthResearchInstitute,LabFB125,268GrosvenorStreet,London,ON,CanadaN6A4V2
2DepartmentofPsychiatry,UniversityofWesternOntario,London,ON,CanadaN6A3K7
3MedicalandScientificofHG&HPharmaceuticals(Pty)Ltd.,193BryanstonDrive,Bryanston2192,SouthAfrica
4DepartmentofPsychiatry,SchoolofMedicine,UniversityofPuertoRico,SanJuan,PR00936-5067,USA
5MedicalandScientificAffairs,PLThomas&Co.,Inc.,Morristown,NJ07960,USA
6DepartmentofPsychiatry,IslandMedicalProgram,UniversityofVictoria,UniversityBritishColumbiaExtendedMedicalCampus,
Victoria,BC,CanadaV8W2Y2
7DepartmentofPsychiatry,NorthernOntarioSchoolofMedicine,ThunderBay,ON,CanadaP7B5E1
CorrespondenceshouldbeaddressedtoSimonChiu;schiu3207@rogers.com
Received21May2014;Revised16August2014;Accepted2September2014;Published19October2014
AcademicEditor:KuzhuvelilB.Harikumar
Copyright¬©2014SimonChiuetal.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,
whichpermitsunrestricteduse,distribution,andreproductioninanymedium,providedtheoriginalworkisproperlycited.
Introduction.ConvergingevidencesuggeststhatPDE-4(phosphodiesterasesubtype4)playsacrucialroleinregulatingcognition
viathePDE-4-cAMPcascadesignalinginvolvingphosphorylatedcAMPresponseelementbindingprotein(CREB).Objective.The
primaryendpointwastoexaminetheneurocognitiveeffectsofextractSceletiumtortuosum(Zembrin)andtoassessthesafetyand
tolerabilityofZembrinincognitivelyhealthycontrolsubjects.Method.Wechosetherandomizeddouble-blindplacebo-controlled
cross-overdesigninourstudy.Werandomizednormalhealthysubjects(totalùëõ = 21)toreceiveeither25mgcapsuleZembrin
orplacebocapsuleoncedailyfor3weeks,inarandomizedplacebo-controlled3-weekcross-overdesign.Weadministeredbattery
ofneuropsychologicaltests:CNSVitalSignsandHamiltondepressionratingscale(HAM-D)atbaselineandregularintervalsand
monitoredsideeffectswithtreatmentemergentadverseeventsscale.Results.21subjects(meanage:54.6years¬±6.0yrs;male/female
ratio: 9/12) entered the study. Zembrin at 25mg daily dosage significantly improved cognitive set flexibility (ùëÉ < 0.032) and
executive function(ùëÉ < 0.022),compared withtheplacebo group.Positivechanges inmoodandsleepwere found.Zembrin
waswelltolerated.Conclusion.ThepromisingcognitiveenhancingeffectsofZembrinlikelyimplicatethePDE-4-cAMP-CREB
cascade,anoveldrugtargetinthepotentialtreatmentofearlyAlzheimer‚Äôsdementia.ThistrialisregisteredwithClinicalTrials.gov
NCT01805518.
1.Introduction life, reducing age-related cognitive decline, and preventing
Alzheimer‚Äôsdementia[1].Preventiveproactivehealthstrate-
Withtheglobalincreaseinlifeexpectancy,productivecog- giesexploremultipletoolsandresourcestoboost‚Äúcognitive
nitive aging focuses on longevity and enhancing quality of reserve‚Äù and to consolidate ‚Äúcognitive maintenance‚Äù [2, 3].

## Page 2

2 Evidence-BasedComplementaryandAlternativeMedicine
RecentresearchadvancesinagingandAlzheimer‚Äôsdementia OCH3 OCH3
(AD) have provided evidence to define the clinical stages
OCH3 OCH3
of AD into three stages: (1) preclinical; (2) mild-cognitive
impairment(MCI),and(3)AD[4].Neuroimagingpositron
emissiontomography(PET)approachtolabelamyloid-ùõΩ1-42
(AùõΩ1-42)peptideshowedthatinthepreclinicalstageAùõΩ1-42
startedtoaccumulateinthevulnerablebrainsofindividuals
1to2decadespriortocognitiveimpairment[5].Thedisease
N OH N O
burden of AD can be present before any symptoms appear.
Thisfindingopensupnewavenuesofproactiveinterventions CH3 CH3
at the asymptomatic stage with the objective to ‚Äúpostpone Mesembrenol Mesembrenone
the onset, reduce the risks of, or completely prevent the
clinicalstagesofAD‚Äù[6].Inthisrespectdietaryinterventions
through hitting multiple targets for AD: amyloid-AùõΩ1-42
OCH3 OCH3
aggregation,neuroinflammation,synapticplasticity,andtau
OCH3 OCH3
(microtubule-associatedprotein)phosphorylation,canoffer
uniqueadvantagestoattenuatetheself-propagatingcourseof
ADandtopreventthetransitionfromMCItoearlyAD[7].
There has been growing interest in the crucial role of
intracellularsecondmessengers:cAMPandcGMP,inregu-
lating age-associated gene expression and cognitive decline N OH N O
[8]. The dual second messengers induce signal cascades
CH3 CH3
involved in neuronal survival, apoptosis, and synaptic plas-
Mesembranol Mesembrine
ticity and neural connectivity. The cAMP-response element
binding protein (CREB) appears to orchestrate the signal Figure1:ChemicalstructuresofalkaloidsisolatedfromSceletium
transduction from gene activation to effector responses of tortuosum: mesembrine, mesembrenol, mesembrenone, and mes-
cognition.Theagingprocessislinkedtodifferentialchanges embranol.
ingeneexpressionofPDEsubtypes[9].Intherodentspecies,
PDE-4 gene knockout resulted in memory improvement
in the rodent species [10]. Rolipram, the prototypal PDE-4
antagonist, reversed AùõΩ25-35 and AùõΩ1-40 peptide-induced
healthy subjects. Previously, a RCT trial reported that daily
memory deficits in the Morris-water maze test (MWM)
oraldosageof25mgfor3monthswassafeandwelltolerated
and passive avoidance tasks [11]. Results from translational
[21].OurstudydemonstratedforthefirsttimethatZembrin
research studies raise the issue of whether consumption of
improved executive function and cognitive flexibility in
PDE-drivennutraceuticalsinmiddle-agedadultscanprovide
healthycontrolsubjects.
neuroprotectiveeffectsinpreventingordelayingtheonsetof
cognitivedecline.
Promisingfindingshavebeenreportedonthecognitive 2.MaterialsandMethods
benefits of early intervention with nutraceuticals targeting
2.1.StudyDesign. Thepilotstudywasarandomizedplacebo-
PDE-4-cAMP-CREB signaling [12, 13]. Resveratrol isolated
controlledcross-overstudyusingafixedoraldosageof25mg
fromgrapesispresentintheredwineandhasbeenshown
extractSceletiumtortuosum(Zembrin)takenoncedaily.The
to modify cognition through the PDE-4-cAMP metabolic
study was conducted at a single center in Puerto Rico (a
pathway[14].Caffeine(1,3,5-trimethylxanthine),widelycon-
territoryadministeredbytheUSA).Thedurationofthestudy
sumedascoffeeintheworld,targetsbothPDEsubtypes4and
was9weeks.
5 (PDE-4, PDE-5) and adenosine-2 receptor [15]. Epidemi-
ologicalstudiesindicatethatcoffee/caffeineconsumptionis
likely to be associated with a reduced risk of AD [16, 17]. 2.2. Study Product. Extract Sceletium tortuosum (Zembrin)
In the prospective Cardiovascular Risk Factors, Aging, and wasmanufacturedaccordingtoEuropeanUnionGoodMan-
Dementia(CAIDE)study,dailycoffeedrinkingtotaling3‚Äì5 ufacturing Practice (GMP). The extract was in the form of
cupsperdayatmidlifereducedADriskbyabout65%atlate a fine dry powder with the dry plant material:extract ratio
life[18]. of 2:1, standardized to a total alkaloid content for the four
In the recombinant PDE4 in vitro assay, Sceletium tor- main Sceletium alkaloids (mesembrenone, mesembrenol,
tuosum (Zembrin) selectively inhibited PDE-4 with IC50 mesembrine, and mesembranol) of 0.4%. The contents of
(inhibitory constant) value of 8.5ùúág/mL. Mesembrenone, a thefouralkaloidswerequantifiedusinghighpressureliquid
majoralkaloidisolatedfromtheextract(Figure1),wasactive chromatography(HPLC)analysisagainstvalidatedanalytical
ininhibitingPDE4withanIC50valueof<1ùúáM[19].Thein referencestandards.Eachactiveopaquewhitegelatincapsule,
vitrofindingsareconsistentwithZembrininMWMtest[20]. lot number NG022, contained 25mg of extract Sceletium
Inourproof-of-conceptrandomizedplacebo-controlled tortuosum(Zembrin)lotnumberSCE0411-1605,equivalentto
study, we hypothesize that Zembrin enhances cognition in 50mgofacultivatedselectionoftraditionallyusedSceletium

## Page 3

Evidence-BasedComplementaryandAlternativeMedicine 3
tortuosumplantmaterial.Identical-lookingplacebocapsules, events were administered at baseline and the end of weeks
lotnumberNG009,containednoherbalextract.Placeboand 3, 6, and 9. The study was fully approved by Aspire Inc.
Zebrine capsules were identical in size, transparency, color, (CA,USA),acommunityinstitutionalresearchethicsboard
andtaste. granting approval and monitoring clinical trials. Research
subjects participated in the study only after they were fully
explained the protocol and signed the informed consent
2.3.SubjectRecruitment. Potentialresearchsubjectsaged45
form.
to 65 years old of either gender were recruited at a single
site in Puerto Rico (US) through advertisement. They were
required to undergo screening with the structured clinical 2.5. Statistics. We used the one-way analysis of variance
interview for psychiatric disorders: Mini-Neuropsychiatric (ANOVA) followed by the post hoc Tukey HSD test to
InterviewMINI-PlustoidentifythepresenceofanyDSMIV- examine the difference in changes in neurocognitive data
R psychiatric disorders [22]. Subjects were excluded if they from Zembrin-treated group and the placebo group, as
hadanysignificantanduntreatedmedicaldisorders,includ- compared with baseline. The level of significance was set at
ing severe uncontrolled or marginal glycemic controlled ùëÉ < 0.05 for two-tailed paired t-test and nonpaired t-test.
diabetes mellitus, recent myocardial ischemia or infarction, Cohen‚Äôsdstatisticswasusedtoevaluatethetreatmenteffect
unstableangina,uncontrolledhypertension,renalfailureand sizesoftheplaceboandZembringroups.ForCohen‚Äôsdeffect
serious renal diseases, chronic active hepatitis, acute hep-
size,apositivevalue>0.0indicatesthatZembrintreatment
atitis,cirrhosisofliver,AIDS,malignancy,andneurological
isbetterthanplacebo,whereasanegativevalue<0.00shows
disorders:epilepsy,recentcerebrovasculardisease,andrecent thattheplaceboisbetterthanZembrin,undertheconditions
traumaticbraininjury.Subjectswithactivesuicidalriskwere ofthestudyprotocol.ForCohen‚Äôsd,thehigherthevalueof
also excluded. Pregnant females and subjects with HAM-D Cohen‚Äôsd,thelargerthetreatmenteffect.Chi-squarestatistics
(Hamilton depression) [23] score >/‚àí8 and/or body mass and Kendall‚Äôs tau were used to determine the frequency of
indexBMI>/‚àí30.0werealsoexcluded. adverseevents.
3.Results
2.4. Study Protocol. At baseline, subjects were required to
undergo physical examination, blood chemistry, and urine
3.1.BaselineClinic-Demographics. Atotalof21subjects(male
toxicologicalscreenand12-leadEKG,alongwithneurocog-
to female ratio, 9/12) were recruited at the single research
nitive assessment using the computerized battery of vali-
center in PR (US). The mean age was 54.6 years (range 45
dated neuropsychological tests named CNS Vital Signs. We
to 61 years, SD = 6.0). Two subjects dropped out during
had privileged access to the CNS Vital Signs through an
the placebo phase and three subjects dropped out during
academic-researchcontractwithCNSVitalSignsInc.,USA
the Zembrin phase. During the screening phase, healthy
[24]. The test battery was administered under standardized
subjectswithneithermajormedicaldisordersnorDSMIV-R
conditionsbyqualifiedpersonnel.Thebatteryofneuropsy-
psychiatricdisorderssignedtheconsentformafterthestudy
chological tests was developed to measure the changes in
protocol was fully explained to them. Completer-analysis
9 cognitive domains: composite memory, verbal memory,
criteriawereusedinanalyzingthedata.
visual memory, processing speed, executive function, psy-
chomotorspeed,reaction,complexattention,andcognitive
flexibility.ThesubjectswerealsoadministeredHAM-Dand 3.2.Efficacy. Theprimaryefficacyendpointwasthechangein
treatmentemergentadverseeventsatface-to-faceinterview eightcognitivefunctiondomainsandtheaggregateaverageof
with research clinicians experienced in clinical trials. Sub- theneurocognitivemeasuredefinedasneurocognitiveindex
jects were randomized by the procedure of computerized as measured with the CNS Vital SignR test. The data were
random numbers to either one of the two arms: (1) the analyzed statistically by one-way ANOVA with 3 groups of
activeinvestigationalproductarmreceivedextractSceletium data as shown in Table1. We compared the changes in the
tortuosum (Zembrin) 25mg capsule (abbreviated Zembrin overallperformancescorenamedasneurocognitiveindexas
group);(2)theplaceboarmreceivedplacebocapsule(abbre- thesummedtotalscoreofthe9cognitivedomains:composite
viated placebo group).Duringthe first 3-week phase ofthe memory, verbal memory, visual memory, processing speed,
study blinded to both the researchers and the subjects, the executive function, psychomotor speed, reaction, complex
participantsrandomizedtotheZembringrouptooka25mg attention, and cognitive flexibility (Figure2). For each spe-
capsule of Zembrin once daily orally whereas the placebo cific neurocognitive measure, we also examined whether
group took a placebo capsule once a day orally. At the end the Zembrin group differed from the placebo group. We
ofthefirst3-weekphase,thesubjectswerealloweda3-week evaluatedthechangesincognitivescoreatbaselinewiththe
washout, during which time no capsules were ingested by score at the end of the three weeks of placebo or Zembrin
either group. During the second 3-week switch-over phase, period.Nocross-overeffectwasfoundforeithertheplacebo
theZembringrouptookaplacebocapsuleonceadayorally ortheextractgroups.
andtheplacebogrouptookthe25mgZembrincapsuleonce As shown in Table1 and Figure2, the ANOVA analysis
dailyorally.Duringtheentire9-weekstudyperiod,vitalsigns followedbyTukeyHSDposthoctestindicatedthatthemean
(bloodpressureandpulse)andbodyweightweremonitored. neurocognitive index and score for each separate domain
CNSVitalSignR,HAM-D,andtreatmentemergentadverse differedbetweentheZembrinphaseandtheplacebophase.

## Page 4

4 Evidence-BasedComplementaryandAlternativeMedicine
SNC
fo
serusaem
evitingocoruen
ni
egnahC
Zembrin effects on cognitive domains of CNS battery of tests
30
25
20
15
10
5
0
‚àí5
‚àí10
‚àí15
‚àí20
Measures
Zembrin
Placebo
)%(
yrettab
tset
...xedni
evitingocorueN
yromem
etisopmoC
yromem
labreV
yromem
lausiV
deeps
gnissecorP
noitcnuf
evitucexE
deeps
rotomohcysP
emit
noitcaeR
noitnetta
xelpmoC
ytilibixefl
evitingoC
andbettercopingwithstressanddepressingevents[21].The
baselineHAM-Dscoresinbothgroupswere<6.0atthestart
ofthestudy.AsshowninTable2,fortheZembringroupthe
change from the baseline value of 2.17 (SD = 1.9) to 1.22
(SD = 1.9) after 3 weeks represented a 26.9% change. For
theplacebogroup,thebaselineHAM-Dwas1.95(SD = 2.1)
and changed to 1.68 (SD = 1.5) after 3 weeks on placebo,
representing a 13.8% decrease in HAM-D. In view of the
substantialvariation,thedifferencefailedtoreachstatistical
significance.
We observed that subjects taking Zembrin reported
improvement in the subjective quality of their sleep on the
HAM-D subscale. Whilenoneofthesubjectshad ahistory
of insomnia, the data showed that Zembrin had a positive
effectononsetofsleep,ascomparedwiththeplacebogroup.
Weobservedthatthemeanratingofsleeponsetatbaseline,
0.76 (SD = 1.14), changed to 0.43 (SD = 0.93) at week 3
(paired t test, t = 2.09, df = 20, ùëÉ = 0.049, 2-tailed). No
significant change was noted in the placebo-treated group
regarding the variable: sleep-onset difficulty: ùëÉ = 0.606,
pre-andposttreatmentt-test.Inthisstudy,Zembrinexerted
an overall improvement in the quality of sleep in a normal
community sample. Our results corroborated the findings
fromarecentsafetyandtolerabilitystudyofextractSceletium
tortuosum(Zembrin)onsleepquality[21].
Figure 2: Cognitive effects of Zembrin extract in healthy sub-
jects: Zembrin-treated subjects and placebo-treated subjects were
administeredCNSVitalSignRbatteryofneuropsychologicaltestsat
3.3. Safety and Tolerability. Extract Sceletium tortuosum
baselineandattheendofthetreatmentperiod.Cognitivedomains
(Zembrin)wassafeandwelltolerated.Therewerenochanges
werederivedfromCNSVitalSignRtests.
in blood pressure, pulse, temperature, and weight in either
theZembringrouportheplacebogroup(Table3).Regarding
thetreatmentemergentadverseevents(Table4)theZembrin
Zembrin significantly improved cognitive flexibility (ùëÉ < group reported transient gastrointestinal discomfort (9.5%)
0.022)andexecutivefunction(ùëÉ < 0.032)ascomparedwith which resolved spontaneously, and the clinician did not
placebo.Zembrinimprovedprocessingspeed,psychomotor ascribe a direct link to the Zembrin. This study agrees
speed,andcomplexattention,butANOVAanalysisfailedto with a recent published RCT study reporting the placebo
findastatisticalsignificancebetweenthegroupsincomposite groupcomplainedofmorefrequentadverseeventsthanthe
memory, verbal memory, and visual memory. Both the Sceletiumtortuosum(Zembrin)group[21].Theincidenceof
placeboandZembringroupsshowednegativechangeinthe treatmentemergentadverseevents(TEAE)classedas‚Äúmild‚Äù
domain of visual memory. In a separate analysis, we found and‚Äúmoderate‚Äùwasquitelow.Thecommonsideeffectsinthe
that the final visual memory score differed only minimally placebogroupconsistedofmildskinirritation(10%),appetite
from the baseline value. Furthermore, the baseline visual decrease(10%)andweightloss(15%),andinterruptedsleep
memoryscoreofplacebogroupremainedunchangedatthe (10%).
endofthe3rdweekperiod(39.4(SD = 32.0)versusaverage We used Kendall‚Äôs tau ùëê coefficient (a nonparametric
39.6(SD = 29.0)).Weinterpretthefindingstoberelatedto statistical measure of association between two measured
practiceeffect.Thecohortofcognitivelynormalsubjectsmay quantities and unaffected by deviations from the normal
bemoresensitivetothenegativepracticeeffects. datadistribution)toanalyzethedirectionofchangesinthe
Regarding the neurocognitive data, Cohen‚Äôs d statistics frequencyandintensityofthecomplaintsandsymptomsas
estimateofeffectsizefavoredZembringroupovertheplacebo listedinthetreatmentemergentadverseevents(TEAE)scale.
group.WefoundrobustCohen‚Äôsdeffectsizefortwocognitive The tau ùëê coefficients are interpreted as follows: 0 indicates
domains: 1.47 for cognitiveflexibility and 1.49 for executive no association, 0‚Äì0.1 weak association, 0.1‚Äì0.3 moderate
function.Forprocessingspeed,astrongCohn‚Äôseffectsizewas associations,and0.3‚Äì1.0strongassociation.Wedetermined
found: 2.88, whereas for psychomotor speed Cohen‚Äôs d was the tau ùëê coefficients for the baseline to end of 3rd week
0.95 and a small effect in the domain of complex attention: treatment with Zembrin and with placebo. The findings
0.16. indicatedtheZembringroupshowedselectiveimprovement
The subjective ratings of generalized well-being and in the following subcategories: irritability (tau ùëê = 0.33),
positive mood states in our study agreed well with a recent drowsiness(tau ùëê = 0.30),memoryproblems(tau ùëê = 0.25),
safety and tolerability study on extract Sceletium tortuosum anxiety (tau ùëê = 0.24), confusion (tau ùëê = 0.17), skin
(Zembrin)inhealthysubjectswhoreported‚Äúupliftedspirits‚Äù irritation (tau ùëê = 0.16), chest pain (tau ùëê = 0.15), stool

### Table 1 (Page 4)

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

## Page 5

Evidence-BasedComplementaryandAlternativeMedicine 5
Table1:CognitiveoutcomemeasuresofZembrineffectsonneurobatterytestsafter3weeksofZembrintreatmentandplacebotreatment.
Outcomemeasure MeanscoreandSEMatbaselineandafterZembrinandafterplacebotreatment
CNSVitalSigns After3weeksZembrin After3weeksofplacebo
ùêπvalues ùëÉvalues
Baseline
Keydomains: (ùëÅ=17) [%change] (ùëÅ=18) [%change]
ùêπ=.992 ùëÉ=0.376
Neurocognitiveindex(NCI) 36.3(4.5) 43.9(6.8) [7.6] 47.2(7.7) [10.9]
Compositememory 38.9(5.3) 32.9(8.5) [‚àí6.0] 41.0(9.0) [2.1] ùêπ=.269 ùëÉ=0.765
ùêπ=.302 ùëÉ=0.740
Verbalmemory 36.9(5.1) 41.6(7.7) [4.7] 43.7(8.9) [6.8]
Visualmemory 45.6(5.5) 29.5(8.6) [‚àí16.1] 39.6(7.2) [‚àí6.0] ùêπ=1.403 ùëÉ=0.253
Processingspeed 56.7(5.7) 77.4(6.8) [20.7] 54.7(8.8) [‚àí2.0] ùêπ=2.557 ùëÉ=0.085
‚àóùêπ=3.603 ‚àóùëÉ=0.032
Executivefunction 36.8(5.4) 60.8(6.6) [24.0] 50.1(7.7) [13.3]
Psychomotorspeed 54.8(5.6) 60.4(8.2) [5.6] 52.4(8.5) [‚àí2.4] ùêπ=.252 ùëÉ=0.778
ùêπ=1.686 ùëÉ=0.193
Reactiontime 45.8(5.1) 58.1(6.3) [12.3] 59.1(6.8) [13.3]
ùêπ=.407 ùëÉ=0.667
Complexattention 38.5(5.3) 46.2(7.8) [7.7] 44.9(8.5) [6.4]
Cognitiveflexibility 35.4(5.3) 60.2(6.5) [24.8] 49.7(7.5) [14.3] ùêπ=4.016 ‚àóùëÉ=0.022
‚àó StatisticallydifferentatùëÉ<0.05two-tailed.
Table2:ZembrinextracteffectonHAM-Dinhealthycontrolsubjects.
ùëÉvalue Effectsize:
AverageHAM-D SD
1-tailed %change
BeforeZembrin(ùëÅ=18) 1.67 1.9 ùëÉ=0.075 26.9%
AfterZembrin(ùëÅ=18) 1.22 1.9 decreaseonHAM-D
Beforeplacebo(ùëÅ=19) 1.95 2.1 ùëÉ=0.289 13.8%
Afterplacebo(ùëÅ=19) 1.68 1.5 decreaseonHAM-D
discoloration(tau ùëê=0.12),andpoorhearing(tau ùëê=0.11). ofdailyliving(IADL).InthepreclinicalstageofAD,thetwo
Fortheplacebogroup,therewasanassociationwithdecrease measuresofexecutivefunction:colorwordinterferencetest
inappetite(tau ùëê=0.20)andweightgain(tau ùëê=0.26). (CWIT) and verbal fluency (VF) predicted decline in cog-
nitivesetswitching[28].Twospecificmeasuresofexecutive
function,Strooptestandsematicfluencytest,werefoundto
4.Discussion correlatewithreducedglucoseutilizationasexaminedwith
PET ligand, [18F] fluorodeoxyglucose (FDG) [29]. Decline
Ourstudydemonstratedforthefirsttimeinhealthysubjects in executive function has been localized in the left lateral
ZembrinextractinselectivelytargetingPDE-4significantly prefrontalcortex,thecrucialbrainregionrelatedtothetriad
enhanced executive functionand cognitiveflexibility. Zem- componentsofthecognitivecontrol:workingmemory,task
brin was highly tolerated. Executive function encompasses switching,andinhibitorycontrol[30,31].
higher-order cognitive processes such as working memory, The cognitive effects of Zembrin are consistent with
attentioncontrol,responseinhibition,andconceptformula- the in vitro structure-activity relationship analysis showing
tionandisthoughttobeprimarilydrivenbytheprefrontal cognition is selectively mediated via the long isoform of
cortex. Cognitive intact individuals can modify behavioral PDE-4D3 [32]. In the PDE assay system using the human
repertoire and cognitive set in response to changing envi- recombinant PDE-4B, mesembreonone was 17 times more
ronmental cues and contexts and hence can streamline potent than mesembrine and 34 times more active than
the activities of daily living (ADL) [25, 26]. In general, mesembrenolininhibitingPDE-4Bbinding[19,21,33].The
executivefunctionsarecrucialformaintainingthecognitive IC50 values for mesembrenone were 470nM, followed by
homeostasisoftheindividualsinordertomeetthedemands mesembrine7800nM and mesembrenol 10,000nM. In the
ofdailyliving. macaque monkey species, rolipram, the prototypal PDE-
There is a growing body of evidence to indicate that 4 antagonist, has been found to improve object retrieval
impairment in executive functioning is present at the very performance[34].ZembrindistinguishesfromotherPDE-4
earlieststageofAlzheimer‚Äôsdementiabeforemarkedmemory agonistsintheabsenceofgastrointestinalsideeffects[35].
deficits appear. In a large cohort study of healthy control WeproposethemodelofPDE-coupledcAMPcascadeto
along with early Alzheimer‚Äôs dementia (AD) [27] and mild explainthecognitiveeffectsofZembrin(Figure3).Zembrin
cognitive impairment (MCI) (ùëõ = 793) subjects, multiple isbehavingastheputativePDE-4allostericmodulatorinter-
regression analysis showed a significant relation between actingwithPDE-4-coupledsystem.Thesynapticspinoffsin
executivefunctionandimpairmentininstrumentalactivities aging are seen in changes in modulating the downstream

## Page 6

6 Evidence-BasedComplementaryandAlternativeMedicine
Table3:Zembrinextractonvitalsignsinhealthycontrolsubjects.
Zembrin:means(SDs);ùëÅ=20 Placebo:means(SDs);ùëÅ=20
Before After ùëÉvalue Before After ùëÉvalue
SystolicBP 115.0(13.2) 116.7(15.8) ns 117.5(17.4) 116.3(13.8) ns
DiastolicBP 72.3(8.7) 73.4(10.4) ns 76.0(9.4) 74.5(7.5) ns
Pulse 73.4(7.2) 74.6(7.1) ns 74.4(11.9) 75.7(9.3) ns
Temperature 36.2(0.2) 36.1(0.2) ns 36.3(0.3) 36.3(0.3) ns
Weight(lbs) 163.1(26.0) 162.6(26.7) ns 162.7(26.0) 163.5(26.8) ns
Ns:notsignificantatùëÉ<0.05level.
Table4:Treatmentemergentadverseevents:Zembrinversusplacebo.
Minimal=1 Mild=2 Moderate=3 Severe=4
Category Signs/symptoms
Z P Z P Z P Z P
Head Headache 0 0 0 0 0 5 0
Eyes Eyeirritation 0 0 0 0 0 0 0 5
Eyes Visionblurred 0 0 5 0 0 0 0 5
Ears Poorhearing 5 5 0 0 0 0 0 0
Mouth Hypersalivation 0 5 0 0 0 0 0 0
Mouth Dentalproblems 0 0 0 0 5 5 0 0
Chest Chestpain 0 0 5 0 0 0 0 0
Chest Coughing 0 5 0 0 0 0 0 0
Gastrointestinal GIdiscomfort 0 0 0 5 0 0 9.5 0
GI Nausea 0 0 0 0 5 0 0 0
GI Vomiting 0 0 0 0 5 0 0 0
GI Constipation 0 0 0 0 0 0 5 0
GI Flatulence 0 0 0 5 0 0 5 0
GI Appetiteincrease 5 0 0 0 5 0 0 0
GI Appetitedecrease 0 5 0 10 0 5 0 0
GI Weightgain 14 0 0 0 0 0 0 0
GI Weightloss 5 10 0 15 0 0 0 0
GI Thirstincrease 0 0 5 0 5 0 0 0
GU Increasedfrequency 0 0 0 5 0 5 0 0
GU Genitaldiscomfort 0 0 0 0 5 0 0 0
GU Increasedlibido 0 0 0 0 0 5 0 0
Musculoskeletal Muscle/bone/jointpain 5 0 0 5 0 10 0 5
MS Rigidity(muscle) 0 0 0 0 5 0 0 0
Skin Skinirritation 0 0 0 10 0 10 0 0
Skin Hairproblems 0 5 0 5 0 5 0 0
Psychiatric:PS Tiredness/fatigue 0 0 5 0 0 0 5 0
PS Overarousal 0 5 0 0 0 5 0 0
PS Difficultyfallingasleep 0 0 0 10 0 0 0 0
PS Earlymorningawakenings 5 5 0 5 0 0 0 0
PS Interruptedsleep 0 0 0 10 0 0 0 0
PS Drowsiness 0 0 0 0 0 0 5 0
PS Confusion 0 0 0 0 5 0 0 0
PS Concentrationdifficulty 0 0 0 0 0 0 5 0
PS Memoryproblems 0 5 0 0 5 0 0 0
PS Depression 0 0 0 0 5 0 0 0
PS Anxiety 0 5 0 0 5 0 0 0
PS Irritability 0 0 0 5 0 0 0 0
NB:nolife-threateningadverseeventswerefound.
Frequencyofadverseevents‚â•5%.Z:Zembrintreatedgroup.P:placebotreatedgroup.

## Page 7

Evidence-BasedComplementaryandAlternativeMedicine 7
5Û≥∞Ä
AMP
AC
Zembrin extract
PDE
ATP Balanced
cAMP pool
PDE-4inhibitor
PKA
CREB
pCREB binding
Genes
protein
‚Äúon‚Äù ‚Äúoff‚Äù
Synaptic
plasticity
proteins
Figure 3: PDE-4/cAMP/CREB cascade in cognition: bidirectional regulation of cyclicAMP (cAMP) homeostasis is achieved through
adenylatecyclase(AD)andphosphodiesterase(PDE)subtype4.cAMPisactivatedviaeitherPDE-4inhibitionorhormone/neurotransmitter-
stimulatedadenylatecyclase(AD).ThecAMP-dependentproteinkinaseA(PKA),onceactivatedthroughallostericsite,canphosphorylate
cAMPresponseelementbindingprotein(CREB)toformphosphorylatedCREB:pCREB.pCREBassociateswithtranscriptioncoactivator,
CREBbindingproteintoinitiatetranscriptionandtranslation.TheCREB-mediatedgeneexpressioncontributestowardslong-andshort-term
memoryandsynapticplasticity.ZembrinextractmodulatesPDE-4andparticipatesinPDe-4/cAMP/CREBcascadeincognition.TheCREB-
linkedgeneexpressionhasbeenshowntobeimpairedinADmodel.ATP:adenosinetriphosphate;cAMP:cyclicadenosinemonophosphate;
Û∏Ä† Û∏Ä†
adenylatecyclase:AC;5AMP:5 adenosinemonophosphate;CREB:cAMPresponseelementbindingprotein;pCREB:phosphorylatedCERB;
PKA:phosphokinaseA.
CREB-mediatedeffectorresponsescomprisingneurogenesis, analysis on the emotion-matching task [39]. Nevertheless,
synapseremodeling,andneuron-microgliareciprocalregu- theemergingbodyofevidencesuggeststhatPDE-4-cAMP-
lation[35]. CREBsignalcascadeplaysacrucialroleinregulatingsleep-
The results of our study on the cognitive enhancing wakefulnesscycleandaffectiveregulation.Insleepdepriva-
effectsofZembrinextract,however,maynotbeinterpreted tion model, the C57BL/6J mice when sleep deprived for 5
solely in the context of PDE-4 modulation. The family of hoursshowedselectiveimpairmentincAMP/phosphokinase
mesembrine alkaloids from Zembrin exhibit serotonergic A-dependent synaptic plasticity which is reflected in the
propertiesincompetingforserotonintransportersiteinvitro long-termpotentiation(LTP)paradigm,inthehippocampus.
[23,24].Serotoninisknowntoplayacentralroleindecision [40].Geneticknock-downofPDE-4Denzyme:PDE4d(‚àí/‚àí)
processing and attentional set shifting [36]. Very recently, mice displayed an antidepressant phenotype in two behav-
citalopram,theselectiveserotoninreuptakeinhibitor(SSRI), ioral models: the Porsolt forced swim test and the acoustic
hasbeenshowntoreducetheCSFamyloidAùõΩloadinboth startleresponse[41].Noadversechangeswerenotedinthe
normalhumansubjectsandintransgenicmice[37].Hence, sensorimotor gating deficits. Taken together, the potential
serotonin signaling may synergize with PDE-coupled camp anxiolytic/antidepressantandsleep-promotingpropertiesof
cascadeinmodulatingage-relatedcognitionchanges[38]. Zembrinwarrantfurtherinvestigationsintheelderly.
OurinitialsurreptitiousfindingsofZembrininbringing
aboutpositivechangesinsleepandmoodareonlyprelimi-
naryandhavetobeinterpretedwithcaution.Averyrecent 5.Conclusion
functional magnetic resonance imaging fMRI study found
region-specificbrainactivationeffectsofZembrin[39].Acute Despitethemethodologicallimitationsofsmallsamplesize,
administrationofZembrinextractinnormalhealthysubjects theshorttreatmentperiod,andthesingledosage,wedemon-
dampened amygdala reactivity to fearful faces under low stratedforthefirsttimethatZembrinenhancedcognitionin
perceptual load conditions, along with reduced coupling of thedomainsofexecutivefunctioningandcognitiveflexibility
amygdala-hypothalamusasshownbyfollow-upconnectivity inhealthysubjects.Wewillextendourstudytothecohortof

## Page 8

8 Evidence-BasedComplementaryandAlternativeMedicine
elderly subjectsto furtherinvestigatewhetherZembrin can andconsistentlywiththeZembrinstudygroupregardingthe
delay or reverse the course of age-related cognitive decline roleofdietarysupplementstoADdrugdevelopment.Allthe
andADaswellaspreventtheconversionfromMCItoAD. authors have contributed ideas towards the paper and have
OurstudyofthecognitivebenefitsofZembrinhighlightsthe criticallyreviewedthefinaldraft.
pivotalroleofnutraceuticalsinusheringaneweraofpreclin-
ical AD preventive program starting at midlife towards old Acknowledgments
age.Weanticipatethatbiotechnologyadvanceswillaccelerate
thetransformationofPDE-4molecularsignaturestoanew The Zembrin study group express their sincerest gratitude
classofpromisingdrugcandidatesforthetreatmentofAD. for participants for their contribution to the success of this
clinicalstudy.ThestudywasfinanciallysupportedbyHG&H
Pharmaceuticals(Pty)Ltd.,Bryanston,SouthAfrica,andby
Disclosure
PLThomas&Co.Inc.Morristown,NJ,USA,andmanaged
NigelGerickeB.Sc(Honors),MBBChistheDirector,Medical by Lawson Health Research Institute of the University of
and Scientific, of HG&H Pharmaceuticals (Pty) Ltd., the WesternOntario,London,Ontario,Canada.
company that has developed extract Sceletium tortuosum
(Zembrin), and a trustee in a trust that owns a minor References
shareholdinginHG&HPharmaceuticals.ValdimirBadmeav,
M.D. and Ph.D., was the past Director of Medical and [1] P.Ljubuncic,A.Globerson,andA.Z.Reznick,‚ÄúEvidence-based
Scientific Affairs for PL Thomas Ltd, the North American roadstothepromotionofhealthinoldage,‚ÄùJournalofNutrition,
HealthandAging,vol.12,no.2,pp.139‚Äì143,2008.
distributorofZembrin(Zembrin).
[2] L. Nyberg, M. Lo¬®vde¬¥n, K. Riklund, U. Lindenberger, and L.
Ba¬®ckman, ‚ÄúMemory aging and brainmaintenance,‚Äù Trends in
ConflictofInterests CognitiveSciences,vol.16,no.5,pp.292‚Äì305,2012.
[3] K.R.Daffner,‚ÄúPromotingsuccessfulcognitiveaging:acompre-
The authors declare that they have no competing financial hensivereview,‚ÄùJournalofAlzheimer‚ÄôsDisease,vol.19,no.4,pp.
interests. 1101‚Äì1122,2010.
[4] B. T. Hyman, C. H. Phelps, T. G. Beach et al., ‚ÄúNational
Institute on Aging-Alzheimer‚Äôs Association guidelines for the
Authors‚ÄôContribution
neuropathologicassessmentofAlzheimer‚Äôsdisease,‚ÄùAlzheimer‚Äôs
andDementia,vol.8,no.1,pp.1‚Äì13,2012.
Simon Chiu, Nigel Gericke, Michel Farina-Woodbury,
[5] S. Hatashita and H. Yamasaki, ‚ÄúDiagnosed mild cognitive
Vladimir Badmaev, Yves Bureau, and Zack Cernovsky
impairmentduetoAlzheimer‚ÄôsdiseasewithPETbiomarkersof
contributed equally towards the project. Simon Chiu, M.D.
betaamyloidandneuronaldysfunction,‚ÄùPLoSONE,vol.8,no.
and Ph.D., wrote the first draft of the paper. Simon Chiu,
6,ArticleIDe66877,2013.
M.D. and Ph.D., Nigel Gericke, B.S (Honors) and MBBCh,
[6] A.Otaegui-Arrazola,P.Amiano,A.Elbusto,E.Urdaneta,andP.
and Vladimir Badmeav, M.D. and Ph.D., designed the
Mart¬¥ƒ±nez-Lage,‚ÄúDiet,cognition,andAlzheimer‚Äôsdisease:food
study and Yves Bureau, Ph.D., Zack Cernovsky, Ph.D., and
forthought,‚ÄùEuropeanJournalofNutrition,vol.53,no.1,pp.
Michel Farina-Woodbury, M.D., have contributed towards 1‚Äì23,2014.
developing and refining the protocol. Data gathering, [7] J.N.Laditka,S.B.Laditka,E.M.Tait,andM.M.Tsulukidze,
recruitment and clinical assessment of study, and safety ‚ÄúUse of dietary supplements for cognitive health: results of a
monitoring were supervised primarily by Michel Farina- national surveyofadultsintheUnited States,‚ÄùThe American
Woodbury, M.D., at University of Puerto Rico. The authors JournalofAlzheimer‚ÄôsDiseaseandotherDementias,vol.27,no.
thank sincerely Joalex Antongiorgi, M.D., University of 1,pp.55‚Äì64,2012.
Puerto Rico, currently resident in psychiatry, for their [8] E. Benito and A. Barco, ‚ÄúCREB's control of intrinsic and
commitmentand efforts in conductingthe study under Dr. synapticplasticity:implicationsforCREB-dependentmemory
M Woodbury supervision. Hou Jirui Hou, Ph.D., provided models,‚Äù Trends in Neurosciences, vol. 33, no. 5, pp. 230‚Äì240,
2010.
theteamwithhisexpertiseinconductingpreclinicalstudyof
Zembrininanimalmodel.LizGoble,B.A.,hasenlightened [9] E.BollenandJ.Prickaerts,‚ÄúPhosphodiesterasesinneurodegen-
erativedisorders,‚ÄùIUBMBLife,vol.64,no.12,pp.965‚Äì970,2012.
the research group with her interest in anthropological
[10] Y.-F. Li, Y.-F. Cheng, Y. Huang et al., ‚ÄúPhosphodiesterase-
perspectivesondrugdiscoveryinitiativeandhasbeenhighly
4D knock-out and RNA interference-mediated knock-down
helpfulinestablishingtheclinicaltrialinfrastructureforthe
enhancememoryandincreasehippocampalneurogenesisvia
researchteam.Thegraduateresearchtrainees,HanaRaheb,
increasedcAMPsignaling,‚ÄùJournalofNeuroscience,vol.31,no.
B.A. Honors, Kristen Terpstra, B.A. Honors M.S., Morrissa
1,pp.172‚Äì183,2011.
Williams B.A. Honors M.S., and Veronica Sanchez, B.S.
[11] Y.-F. Cheng, C. Wang, H.-B. Lin et al., ‚ÄúInhibition of
Honors and M.S., have assisted in the project in gathering
phosphodiesterase-4 reverses memory deficits produced by
andanalysingthedataunderthesupervisionofYvesBureau, AùõΩ25-35orAùõΩ1-40peptideinrats,‚ÄùPsychopharmacology,vol.
Ph.D.,ZackCernovsky,Ph.D.,SimonChiuM.D.andPh.D., 212,no.2,pp.181‚Äì191,2010.
and Micheal Woodbury M.D. Dr. John Copen, M.D. FRCP, [12] C. A. Saura and J. Valero, ‚ÄúThe role of CREB signaling in
and Dr. Mariwan Husni, M.D. FRCP, have taken persistent Alzheimer‚Äôsdiseaseandothercognitivedisorders,‚ÄùReviewsin
interest incognitiveagingandhaveinteractedproductively theNeurosciences,vol.22,no.2,pp.153‚Äì169,2011.

## Page 9

Evidence-BasedComplementaryandAlternativeMedicine 9
[13] A.Blokland,F.S.Menniti,andJ.Prickaerts,‚ÄúPDEInhibition functionpredictcognitivedeclineinolderadults,‚ÄùJournalofthe
and cognition enhancement,‚Äù Expert Opinion on Therapeutic InternationalNeuropsychologicalSociety,vol.18,no.1,pp.118‚Äì
Patents,vol.22,no.4,pp.349‚Äì354,2012. 127,2012.
[14] J.H.Chung,‚ÄúMetabolicbenefitsofinhibitingcAMP-PDEswith [29] P. Allain, F. Etcharry-Bouyx, and C. Verny, ‚ÄúExecutive func-
resveratrol,‚ÄùAdipocyte,vol.1,no.4,pp.256‚Äì258,2012. tions in clinical and preclinical Alzheimer‚Äôs disease,‚Äù Revue
[15] M.Rivera-OliverandM.D¬¥ƒ±az-R¬¥ƒ±os,‚ÄúUsingcaffeineandother Neurologique,vol.169,no.10,pp.695‚Äì708,2013.
adenosinereceptorantagonistsandagonistsastherapeutictools [30] M.N.BraskieandP.M.Thompson,‚ÄúUnderstandingcognitive
againstneurodegenerativediseases:areview,‚ÄùLifeSciences,vol. deficitsinalzheimer‚Äôsdiseasebasedonneuroimagingfindings,‚Äù
101,no.1-2,pp.1‚Äì9,2014. TrendsinCognitiveSciences,vol.17,no.10,pp.510‚Äì516,2013.
[16] C.Santos, J.Costa,J.Santos,A. Vaz-Carneiro, and N.Lunet, [31] M.L.Schroeter,B.Vogt,S.Frischetal.,‚ÄúExecutivedeficitsare
‚ÄúCaffeine intake and dementia: systematic review and meta- relatedtotheinferiorfrontaljunctioninearlydementia,‚ÄùBrain,
analysis,‚ÄùJournalofAlzheimer‚ÄôsDisease,vol.20,no.1,pp.S187‚Äì vol.135,no.1,pp.201‚Äì215,2012.
S204,2010. [32] A.B.Burgin,O.T.Magnusson,J.Singhetal.,‚ÄúDesignofphos-
[17] M.H.EskelinenandM.Kivipelto,‚ÄúCaffeineasaprotectivefac- phodiesterase4D(PDE4D)allostericmodulatorsforenhancing
torindementiaandAlzheimer‚Äôsdisease,‚ÄùJournalofAlzheimer‚Äôs cognitionwithimprovedsafety,‚ÄùNatureBiotechnology,vol.28,
Disease,vol.20,supplement1,pp.S167‚ÄìS174,2010. no.1,pp.63‚Äì70,2010.
[18] M.H.Eskelinen,T.Ngandu,J.Tuomilehto,H.Soininen,and [33] N. Gericke and A. M. Viljoen, ‚ÄúSceletium‚Äîa review update,‚Äù
M.Kivipelto,‚ÄúMidlifecoffeeandteadrinkingandtheriskof JournalofEthnopharmacology,vol.119,no.3,pp.653‚Äì663,2008.
late-lifedementia:apopulation-basedCAIDEstudy,‚ÄùJournalof [34] K.Rutten,J.L.Basile,J.Prickaerts,A.Blokland,andJ.A.Vivian,
Alzheimer‚ÄôsDisease,vol.16,no.1,pp.85‚Äì91,2009. ‚ÄúSelective PDE inhibitors rolipram and sildenafil improve
[19] A. L. Harvey, L. C. Young, A. M. Viljoen, and N. P. Gericke, objectretrievalperformanceinadultcynomolgusmacaques,‚Äù
‚ÄúPharmacologicalactionsoftheSouthAfricanmedicinaland Psychopharmacology,vol.196,no.4,pp.643‚Äì648,2008.
functional food plant Sceletium tortuosum and its principal [35] R.T.HansenIIIandH.-T.Zhang,‚ÄúSenescent-induceddysregu-
alkaloids,‚Äù Journal of Ethnopharmacology, vol. 137, no. 3, pp. lationofcAMP/CREBsignalingandcorrelationswithcognitive
1124‚Äì1129,2011. decline,‚ÄùBrainResearch,vol.1516,pp.93‚Äì109,2013.
[20] H. Raheb, Y. B. M. Woodbury-Farina, V. Badmaev et al., [36] J. R. Homberg, ‚ÄúSerotonin and decision making processes,‚Äù
‚ÄúTranslational study of standardized Zembrin extract and NeuroscienceandBiobehavioralReviews,vol.36,no.1,pp.218‚Äì
mesembrenone targeting PDE-4 (phosphodiesterase subtype 236,2012.
forregulationofcognitionandmood),‚ÄùinProceedingsofInter-
[37] Y. I. Sheline, T. West, K. Yarasheski et al., ‚ÄúAn antidepressant
national Conference on Bioactive Naturals, London, Canada, decreases CSF AùõΩ production in healthy individuals and in
July2012.
transgenicADmice,‚ÄùScienceTranslationalMedicine,vol.6,no.
[21] H.Nell,M.Siebert,P.Chellan,andN.Gericke,‚ÄúArandomized, 236,ArticleID236re4,2014.
double-blind,parallel-group,placebo-controlledtrialofextract [38] J. J. Rodr¬¥ƒ±guez, H. N. Noristani, and A. Verkhratsky, ‚ÄúThe
Sceletium Tortuosum (Zembrin) in healthy adults,‚Äù Journal of serotonergicsysteminageingandAlzheimer‚Äôsdisease,‚ÄùProgress
Alternative and Complementary Medicine, vol. 19, no. 11, pp. inNeurobiology,vol.99,no.1,pp.15‚Äì41,2012.
898‚Äì904,2013.
[39] D. Terburg, S. Syal, L. A. Rosenberger et al., ‚ÄúAcute effects
[22] DSM-IV-TRAmericanPsychiatricAssociation,Diagnosticand ofsceletiumtortuosum(Zembrin),adual5-HTreuptakeand
StatisticalManualofMentalDisorders,DSM-IV-TRAmerican PDE4inhibitor,inthehumanamygdalaanditsconnectionto
PsychiatricAssociation,4thedition,2000. thehypothalamus,‚ÄùNeuropsychopharmacology,vol.38,no.13,
[23] M.Zimmerman,I.Chelminski,andM.Posternak,‚ÄúAreviewof pp.2708‚Äì2716,2013.
studiesoftheHamiltondepressionratingscaleinhealthycon- [40] C.G.Vecsey,G.S.Baillie,D.Jaganathetal.,‚ÄúSleepdeprivation
trols:implicationsforthedefinitionofremissionintreatment impairscAMPsignallinginthehippocampus,‚ÄùNature,vol.461,
studiesofdepression,‚ÄùJournalofNervousandMentalDisease, no.7267,pp.1122‚Äì1125,2009.
vol.192,no.9,pp.595‚Äì601,2004.
[41] T.L.Schaefer,A.A.Braun,R.M.Amos-Kroohs,M.T.Williams,
[24] C. T. Gualtieri and L. G. Johnson, ‚ÄúReliability and validity of E. Ostertag, and C. V. Vorhees, ‚ÄúA new model of Pde4d
a computerized neurocognitive test battery, CNS vital signs,‚Äù deficiency: genetic knock-down of PDE4D enzyme in rats
ArchivesofClinicalNeuropsychology,vol.21,no.7,pp.623‚Äì643, producesanantidepressantphenotypewithoutspatialcognitive
2006. effects,‚ÄùGenes,BrainandBehavior,vol.11,no.5,pp.614‚Äì622,
[25] A. Martyr and L. Clare, ‚ÄúExecutive function and activities 2012.
of daily living in Alzheimer‚Äôs disease: a correlational meta-
analysis,‚ÄùDementiaandGeriatricCognitiveDisorders,vol.33,
no.2-3,pp.189‚Äì203,2012.
[26] M.S.Albert,‚ÄúChangesincognition,‚ÄùNeurobiologyofAging,vol.
32,supplement1,pp.S58‚ÄìS63,2011.
[27] G. A. Marshall, D. M. Rentz, M. T. Frey, J. J. Locascio, K. A.
Johnson, and R. A. Sperling, ‚ÄúExecutive function and instru-
mentalactivitiesofdailylivinginmildcognitiveimpairment
andAlzheimer‚Äôsdisease,‚ÄùAlzheimer‚ÄôsandDementia,vol.7,no.
3,pp.300‚Äì308,2011.
[28] L.R.Clark,D.M.Schiehser,G.H.Weissberger,D.P.Salmon,
D.C.Delis,andM.W.Bondi,‚ÄúSpecificmeasuresofexecutive

## Page 10

MEDIATORS
of
INFLAMMATION
The Scientific Gastroenterology Journal of
World Journal Research and Practice Diabetes Research Disease Markers
Hhtintpd:/a/wwiw Pwub.hliisnhdinawg iC.coormporation Volume 2014 Hhtitnpd:/a/wwiw Pwub.hliisnhdinawg iC.coormporation Volume 2014 Hhtitnpd:/a/wwiw Pwu.hbliinsdhainwgi .Ccoomrporation Volume 2014 Hhtitnpd:/a/wwiw Pwub.hliisnhdinawg iC.coormporation Volume 2014 Hhtintpd:a//wwiw Pwub.hliisnhdinawg iC.coormporation Volume 2014
Journal of International Journal of
Immunology Research Endocrinology
Hhtitnpd:/a/wwiw Pwub.hliisnhdinawg iC.coormporation Volume 2014 Hhtitnpd:/a/wwiw Pwub.hliisnhdinawg iC.coormporation Volume 2014
Submit your manuscripts at
http://www.hindawi.com
BioMed
PPAR Research Research International
Hhtitnpd:/a/wwiw Pwub.hliisnhdinawg iC.coormporation Volume 2014 Hhtitnpd:/a/wwiw Pwub.hliisnhdinawg iC.coormporation Volume 2014
Journal of
Obesity
Evidence-Based
Journal of Stem Cells Complementary and Journal of
Ophthalmology International Alternative Medicine Oncology
Hhtitnpd:/a/wwiw Pwub.hliisnhdinawg iC.coormporation Volume 2014 Hhtitnpd:/a/wwiw Pwub.hliisnhdinawg iC.coormporation Volume 2014 Hhtitnpd:/a/wwiw Pwub.hliisnhdinawg iC.coormporation Volume 2014 Hhtitnpd:/a/wwiw Pwub.hliisnhdinawg iC.coormporation Volume 2014 Hhtitnpd:/a/wwiw Pwub.hliisnhdinawg iC.coormporation Volume 2014
Parkinson‚Äôs
Disease
Computational and Behavioural AIDS
Mathematical Methods Oxidative Medicine and
in Medicine Neurology Research and Treatment Cellular Longevity
Hhtitnpd:/a/wwiw Pwub.hliisnhdinawg iC.coormporation Volume 2014 Hhtitnpd:/a/wwiw Pwub.hliisnhdinawg iC.coormporation Volume 2014 Hhtitnpd:/a/wwiw Pwub.hliisnhdinawg iC.coormporation Volume 2014 Hhtitnpd:/a/wwiw Pwub.hliisnhdinawg iC.coormporation Volume 2014 Hhtitnpd:/a/wwiw Pwub.hliisnhdinawg iC.coormporation Volume 2014

### Table 1 (Page 10)

|  |
| --- |
| The Scientific
World Journal
Hhtintpd:/a/wwiw Pwub.hliisnhdinawg iC.coormporation Volume 2014 |

### Table 2 (Page 10)

|  |
| --- |
| Gastroenterology
Research and Practice
Hhtitnpd:/a/wwiw Pwub.hliisnhdinawg iC.coormporation Volume 2014 |

### Table 3 (Page 10)

| MEDIATORS
of
INFLAMMATION |
| --- |
| Hhtitnpd:/a/wwiw Pwu.hbliinsdhainwgi .Ccoomrporation Volume 2014 |

### Table 4 (Page 10)

|  |
| --- |
| Journal of
Diabetes Research
Hhtitnpd:/a/wwiw Pwub.hliisnhdinawg iC.coormporation Volume 2014 |

### Table 5 (Page 10)

|  |
| --- |
| Disease Markers
Hhtintpd:a//wwiw Pwub.hliisnhdinawg iC.coormporation Volume 2014 |

### Table 6 (Page 10)

|  |  |  |  |
| --- | --- | --- | --- |
|  |  |  |  |
| Evidence-Based
Complementary and
Alternative Medicine
Hhtitnpd:/a/wwiw Pwub.hliisnhdinawg iC.coormporation Volume 2014 |  |  |  |

